Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Dungarwalla M, Matutes E, Dearden CE . Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol 2008; 80: 469–476.

    Article  CAS  Google Scholar 

  2. Soulier J, Pierron G, Vecchione D, Garand R, Brizard F, Sigaux F et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 2001; 31: 248–254.

    Article  CAS  Google Scholar 

  3. Vainchenker W, Constantinescu SN . JAK/STAT signaling in hematological malignancies. Oncogene 2013; 32: 2601–2613.

    Article  CAS  Google Scholar 

  4. Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, Daniel MT et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 2000; 95: 3891–3899.

    CAS  Google Scholar 

  5. Gritti C, Dastot H, Soulier J, Janin A, Daniel MT, Madani A et al. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. Blood 1998; 92: 368–373.

    CAS  Google Scholar 

  6. Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL et al. Array-based genomic resequencing of human leukemia. Oncogene 2010; 29: 3723–3731.

    Article  CAS  Google Scholar 

  7. Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Dave UP . FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 2011; 118: 3911–3921.

    Article  CAS  Google Scholar 

  8. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008; 205: 751–758.

    Article  CAS  Google Scholar 

  9. Kameda T, Shide K, Shimoda HK, Hidaka T, Kubuki Y, Katayose K et al. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. Int J Hematol 2010; 92: 320–325.

    Article  CAS  Google Scholar 

  10. Bouchekioua A, Scourzic L, de Wever O, Zhang Y, Cervera P, Aline-Fardinet A et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 2013; e-pub ahead of print 14 June 2013; doi:10.1038/leu.2013.157.

    Article  Google Scholar 

  11. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157–163.

    Article  CAS  Google Scholar 

  12. Koskela HLM, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905–1913.

    Article  CAS  Google Scholar 

  13. Couronné L, Scourzic L, Pilati C, Della Valle V, Duffourd Y, Solary E et al. STAT3 mutations identified in human hematological neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica 2013; e-pub ahead of print 19 July 2013; doi:10.3324/haematol.2013.085068.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are indebted to the French hematologists who provided patient samples: B Cazin (Lille); R Garand (Nantes); MJ Grange, V Leblond, F Nguyen Khac, H Merle-Beral, F Valensi, B Varet, I Radford-Weiss, O Hermine, R Delarue, V Levy, JC Brouet, P Rousselot (Paris); G Damaj (Creteil); X Troussard (Caen); S Daliphard, P Cornillet (Reims); D Lusina (Aulnay); K Ghomari (Beauvais); C Bertout (Brest); O Tournilhac (Clermond-Ferrand); M Maynadie (Dijon); V Izydirczyk (Le Havre); E Callet-Bauchu, B Coffier (Lyon); F Lellouche (Quimper). This work was supported by grants from the Institut National du Cancer (INCa), the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Institut Curie, Section de Recherche. This work is a part of the ‘Cancéropole Ile-de-France–Mouse models of human cancer’ program coordinated by M Giovannini. VJ is a recipient of grants from the Association pour la Recherche sur le Cancer (ARC).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M-H Stern.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bellanger, D., Jacquemin, V., Chopin, M. et al. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia 28, 417–419 (2014). https://doi.org/10.1038/leu.2013.271

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.271

This article is cited by

Search

Quick links